ALCOBRA LTD (ADHD) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of ALCOBRA LTD (ADHD) from NEUTRAL to OUTPERFORM on October 28, 2014, with a target price of $4.40.

Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on ALCOBRA LTD (ADHD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply